Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

NuProbe Raises $50 Million for Genomics and Molecular Diagnostics

publication date: Jun 3, 2022

NuProbe Global, with operations in Houston and Shanghai, closed a $50 million funding from China Investors for its genomics and molecular diagnostics business. The company aims to offer the best genomics information to clinicians at a reasonable price. It will use the funds to expand commercial operations, accelerate clinical studies and regulatory submissions for IVD products, and develop new genomics and molecular diagnostics technologies. In 2020, NuProbe merged with CarrierGene Biotech, a Suzhou company developing reproductive diagnostic tests. The latest funding round was co-led by AstraZeneca-CICC Fund, CR-CP Life Science Fund and Panlin Capital. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital